Spots Global Cancer Trial Database for Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
Official Title: Study of EOS884448 Alone, and in Combination With Iberdomide With or Without Dexamethasone, in Participants With Relapsed or Refractory Multiple Myeloma
Study ID: NCT05289492
Conditions
Study Description
Brief Summary: This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide with and without dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Banner MD Anderson, Gilbert, Arizona, United States
Eastern Connecticut Hematology & Oncology, Norwich, Connecticut, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States
ZNA Cadix, Antwerp, , Belgium
Institut Jules Bordet, Brussels, , Belgium
Universitaire Ziekenhuizen KU Leuven, Leuven, , Belgium
CHU Amiens, Amiens, , France
Centre Hospitalier Universitaire de Nantes, Nantes, , France
APHP Hôpital Saint-Antoine, Paris, , France
CHU de Poitiers, Poitiers, , France
CHU Toulouse, Toulouse, , France
Hospital Fundacion Jimenez Diaz, Madrid, , Spain
Contact Details
Name: Iteos Clinical Trials
Affiliation: iTeos Belgium SA
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
